Clinical Trial: Deucravacitinib in PG
Study Status: NOT_YET_RECRUITING
Recruit Status: NOT_YET_RECRUITING
Study Type: INTERVENTIONAL
Official Title: Novel Treatment of Pyoderma Gangrenosum With Deucravacitinib
Brief Summary: The main goal of this study is to see if the study drug called "Deucravacitinib" is safe and effective in treating people with pyoderma gangrenosum (PG).
Detailed Summary:
Sponsor: Dartmouth-Hitchcock Medical Center
Current Primary Outcome: PGA will be used for overall assessment of efficacy.
Original Primary Outcome: PGA will be used for overall assessment of efficacy.
Current Secondary Outcome:
Original Secondary Outcome:
Information By: Dartmouth-Hitchcock Medical Center
Dates:
Date Received: March 20, 2023
Date Started: November 01, 2023
Date Completion: November 01, 2023
Last Updated: July 31, 2023
Last Verified: July 01, 2023